Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04348656 · ClinicalTrials.gov registry record · Phase 3
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
A Phase 3 study, sponsored by Hamilton Health Sciences Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 940
- Enrollment target
NCT04348656 is a Phase 3 study that was terminated before completion, run by Hamilton Health Sciences Corporation. The registered enrollment target is 940 participants.
The verdict
NCT04348656, a Phase 3 study, was terminated before completion, sponsored by Hamilton Health Sciences Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 940 participants
- Enrollment target
Study Summary
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.
Interventions
- BIOLOGICAL Convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 940 participants |
| Start Date | 2020-03-14 |
| Est. Completion | 2021-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04348656
The ClinicalTrials.gov registry entry for NCT04348656 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 940 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hamilton Health Sciences Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent plasma is the first listed.
NCT04348656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04348656 about?
NCT04348656 is a clinical study titled "CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)". There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of conva...
What is the current status of trial NCT04348656?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 940 participants. The study started on 2020-03-14. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT04348656?
The interventions under investigation include: Convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04348656?
This trial is sponsored by Hamilton Health Sciences Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.